Drug intelligence / Profile preview

rosmarinic acid + cerium nanoparticles

Development stage
Preclinical
Lead developer
Central South University
Modality
Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Topical
01

Overview

Rosmarinic acid + cerium nanoparticles (RA/Ce NPs) is a natural-product-derived catalytic nanoplatform (nanozyme) developed by researchers at Central South University and the University of Wisconsin-Madison. Formed via the self-polymerization of rosmarinic acid in the presence of cerium ions, this hybrid coordination polymer nanosystem is designed to address the dual pathological stressors of excessive reactive oxygen species (ROS) accumulation and persistent tissue hypoxia. The redox-switchable Ce3+/Ce4+ centers within the nanoparticles confer robust superoxide dismutase (SOD)- and catalase (CAT)-mimetic catalytic activities, enabling the efficient scavenging of ROS and the simultaneous generation of oxygen to relieve hypoxia. Additionally, the phenolic-carboxylate-carbonyl framework of the polymerized rosmarinic acid provides abundant coordination sites for radiolabeling (e.g., with zirconium-89), allowing for non-invasive positron emission tomography (PET) imaging-guided therapy. RA/Ce NPs are being investigated for the treatment of acute kidney injury (AKI) and diabetic wound healing, where they demonstrate excellent biocompatibility, renal accumulation, and ROS-responsive biodegradation.

Other names
RA-Ce NPsRA/Ce NPscerium-doped rosmarinic acid nanosystemrosmarinic acid-cerium nanocatalystsrosmarinic acid-cerium nanozymes
02

Identity

Drug type
Small Molecules
Originator
Central South University
Modality
Nanoparticles
03

Pharmacology

Route
IntravenousTopical
04

Development

IndicationHighest phaseStatus
acute kidney injury (AKI)PreclinicalActive
chronic woundsPreclinicalActive
diabetic foot complicationsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Central South UniversityOriginator · Lead developer
07

Competitive landscape

Drugs in the lead indication
135

Lead indication: acute kidney injury (AKI)

Most advanced in the lead indication

  1. dopamineApproved
  2. ascorbic acidPhase 4
  3. dapagliflozinPhase 4
  4. enoxaparinPhase 4
  5. ertapenemPhase 4

Beyond the preview

Go deeper on rosmarinic acid + cerium nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosmarinic acid + cerium nanoparticles.

Work on rosmarinic acid + cerium nanoparticles? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call